Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression

Journal of Psychiatric Research

Volumn 96, Issue , 2018, Pages 203-208

  Ricken, Roland ^a   Busche, Marlene ^a   Schlattmann, Peter ^b   Himmerich, Hubertus ^c   Bopp, Sandra ^a   Bschor, Tom ^d,e   Richter, Christoph ^a,f,i   Stamm, Thomas J ^a,j   Heinz, Andreas ^a   Hellweg, Rainer ^a   Lang, Undine E ^h   Adli, Mazda ^a,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Schlosspark Klinik   (Germany)

^e UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

^f Vivantes Wenckebach Klinikum   (Germany)

^g Fliedner Klinik   (Germany)

^h University Psychiatric Clinics (UPK)   (Switzerland)

ⁱ Vivantes Klinikum   (Germany)

^j BRANDENBURG MEDICAL SCHOOL THEODOR FONTANE   (Germany)

more..

Author keywords

Cytokines; Depression; Lithium

Indexed keywords

ANTIDEPRESSANT AGENT; COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LITHIUM; MONOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LITHIUM DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; AGE; BLOOD; BODY MASS; COMBINATION DRUG THERAPY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; SEX FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; BODY MASS INDEX; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LINEAR MODELS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 85032697671     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2017.10.002     Document Type: Article

References (49)

1. Agrawal, S., Gollapudi, S., Gupta, S., Agrawal, A., Dendritic cells from the elderly display an intrinsic defect in the production of IL-10 in response to lithium chloride. Exp. Gerontol. 48:11 (2013), 1285–1292.
2. Audet, M.C., Anisman, H., Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front. Cell Neurosci., 7, 2013, 68.
3. Bai, Y.M., Su, T.P., Li, C.T., Tsai, S.J., Chen, M.H., Tu, P.C., Chiou, W.F., Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. Bipolar Disord. 17:3 (2015), 269–277.
4. Bauer, M., Pfennig, A., Severus, E., Whybrow, P.C., Angst, J., Möller, H.J., Disorders, W.F.o.S.o.B.P.T.F.o.U.D., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J. Biol. Psychiatry 14:5 (2013), 334–385.
5. Beurel, E., Jope, R.S., Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflammation, 6, 2009, 9.
6. Beurel, E., Jope, R.S., Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl. Psychiatry, 4, 2014, e488.
7. Beurel, E., Michalek, S.M., Jope, R.S., Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 31:1 (2010), 24–31.
8. Boufidou, F., Nikolaou, C., Alevizos, B., Liappas, I.A., Christodoulou, G.N., Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect Disord. 82:2 (2004), 309–313.
9. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:5 (2010), 446–457.
10. Fava, M., Rush, A.J., Trivedi, M.H., Nierenberg, A.A., Thase, M.E., Sackeim, H.A., Quitkin, F.M., Wisniewski, S., Lavori, P.W., Rosenbaum, J.F., Kupfer, D.J., Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am. 26:2 (2003), 457–494.
11. Felger, J.C., Lotrich, F.E., Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246 (2013), 199–229.
12. Freland, L., Beaulieu, J.M., Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci., 5, 2012, 14.
13. Guloksuz, S., Cetin, E.A., Cetin, T., Deniz, G., Oral, E.T., Nutt, D.J., Cytokine levels in euthymic bipolar patients. J. Affect Disord. 126:3 (2010), 458–462.
14. Haj-Mirzaian, A., Amiri, S., Kordjazy, N., Momeny, M., Razmi, A., Rahimi-Balaei, M., Amini-Khoei, H., Haj-Mirzaian, A., Marzban, H., Mehr, S.E., Ghaffari, S.H., Dehpour, A.R., Lithium attenuated the depressant and anxiogenic effect of juvenile social stress through mitigating the negative impact of interlukin-1beta and nitric oxide on hypothalamic-pituitary-adrenal axis function. Neuroscience 315 (2016), 271–285.
15. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23 (1960), 56–62.
16. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:12 (2011), 2452–2459.
17. Hiles, S.A., Baker, A.L., de Malmanche, T., Attia, J., Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol. Med. 42:10 (2012), 2015–2026.
18. Hiles, S.A., Baker, A.L., de Malmanche, T., Attia, J., A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav. Immun. 26:7 (2012), 1180–1188.
19. Himmerich, H., Bartsch, S., Hamer, H., Mergl, R., Schönherr, J., Petersein, C., Munzer, A., Kirkby, K.C., Bauer, K., Sack, U., Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. J. Psychiatr. Res. 47:11 (2013), 1751–1759.
20. Himmerich, H., Koethe, D., Schuld, A., Yassouridis, A., Pollmächer, T., Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacol. Berl. 179:2 (2005), 447–451.
21. Hossein, G., Zavareh, V.A., Fard, P.S., Combined treatment of androgen-independent prostate cancer cell line DU145 with chemotherapeutic agents and lithium chloride: effect on growth arrest and/or apoptosis. Avicenna J. Med. Biotechnol. 4:2 (2012), 75–87.
22. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71:2 (2009), 171–186.
23. Isgren, A., Jakobsson, J., Palsson, E., Ekman, C.J., Johansson, A.G., Sellgren, C., Blennow, K., Zetterberg, H., Landen, M., Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain, Behav. Immun. 43 (2015), 198–204.
24. Klein, P.S., Melton, D.A., A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93:16 (1996), 8455–8459.
25. Knijff, E.M., Breunis, M.N., Kupka, R.W., de Wit, H.J., Ruwhof, C., Akkerhuis, G.W., Nolen, W.A., Drexhage, H.A., An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 9:7 (2007), 743–753.
26. Kosloski, L.M., Kosmacek, E.A., Olson, K.E., Mosley, R.L., Gendelman, H.E., GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J. Neuroimmunol. 265:1–2 (2013), 1–10.
27. Leu, S.J., Yang, Y.Y., Liu, H.C., Cheng, C.Y., Wu, Y.C., Huang, M.C., Lee, Y.L., Chen, C.C., Shen, W.W., Liu, K.J., Valproic acid and lithium meditate anti-inflammatory effects by differentially modulating dendritic cell differentiation and function. J. Cell. Physiol. 232:5 (2017), 1176–1186.
28. Lichtblau, N., Schmidt, F.M., Schumann, R., Kirkby, K.C., Himmerich, H., Cytokines as biomarkers in depressive disorder: current standing and prospects. Int. Rev. psychiatry (Abingdon, Engl. 25:5 (2013), 592–603.
29. Lieb, J., The immunostimulating and antimicrobial properties of lithium and antidepressants. J. Infect. 49:2 (2004), 88–93.
30. Maeng, Y.S., Lee, R., Lee, B., Choi, S.I., Kim, E.K., Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. Sci. Rep., 6, 2016, 20739.
31. Maes, M., The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 29:3 (2008), 287–291.
32. Maes, M., Song, C., Lin, A.H., Pioli, R., Kenis, G., Kubera, M., Bosmans, E., In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology 143:4 (1999), 401–407.
33. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:9 (2009), 732–741.
34. Nemeth, Z.H., Deitch, E.A., Szabo, C., Fekete, Z., Hauser, C.J., Hasko, G., Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells. J. Biol. Chem. 277:10 (2002), 7713–7719.
35. Padmos, R.C., Hillegers, M.H., Knijff, E.M., Vonk, R., Bouvy, A., Staal, F.J., de Ridder, D., Kupka, R.W., Nolen, W.A., Drexhage, H.A., A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65:4 (2008), 395–407.
36. Petersein, C., Sack, U., Mergl, R., Schönherr, J., Schmidt, F.M., Lichtblau, N., Kirkby, K.C., Bauer, K., Himmerich, H., Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J. Neural Transm. 122:1 (2015), 102–122.
37. Phiel, C.J., Klein, P.S., Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 789–813.
38. Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27:1 (2006), 24–31.
39. Rapaport, M.H., Guylai, L., Whybrow, P., Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiatr. Res. 33:4 (1999), 335–340.
40. Rapaport, M.H., Manji, H.K., The effects of lithium on ex vivo cytokine production. Biol. Psychiatry 50:3 (2001), 217–224.
41. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163:11 (2006), 1905–1917.
42. Schmidt, F.M., Lichtblau, N., Minkwitz, J., Chittka, T., Thormann, J., Kirkby, K.C., Sander, C., Mergl, R., Fasshauer, M., Stumvoll, M., Holdt, L.M., Teupser, D., Hegerl, U., Himmerich, H., Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J. Psychiatr. Res. 55 (2014), 29–34.
43. Schmidt, F.M., Schroder, T., Kirkby, K.C., Sander, C., Suslow, T., Holdt, L.M., Teupser, D., Hegerl, U., Himmerich, H., Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 239 (2016), 85–91.
44. Schwarz, M.J., Chiang, S., Muller, N., Ackenheil, M., T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain, Behav. Immun. 15:4 (2001), 340–370.
45. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:Suppl. 20 (1998), 22–33 quiz 34–57.
46. Szuster-Ciesielska, A., Tustanowska-Stachura, A., Słotwińska, M., Marmurowska-Michałowska, H., Kandefer-Szerszeń, M., In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol. J. Pharmacol. 55:3 (2003), 353–362.
47. Thase, M.E., Rush, A.J., When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 58:Suppl. 13 (1997), 23–29.
48. Young, J.J., Bruno, D., Pomara, N., A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect Disord. 169C (2014), 15–20.
49. Zhang, M., Jin, W., Zhou, X., Yu, J., Lee, A.J., Sun, S.C., Deregulation of Tpl2 and NF-kappaB signaling and induction of macrophage apoptosis by the anti-depressant drug lithium. Cell. Signal. 21:4 (2009), 559–566.